Filing Flows › Aurinia Pharmaceuticals (AUPH) › Q1 2026
Aurinia Pharmaceuticals (AUPH) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Aurinia Pharmaceuticals (AUPH) reported revenue of $77.7M for the first quarter 2026 (Q1 2026), +24% from a year earlier and +0.8% from the quarter before. Operating margin was 53.3%, net earnings $34.4M (44.2% of revenue).
Aurinia Pharmaceuticals, Q1 2026: revenue $77.7M (+24% year over year), operating margin 53.3%, net earnings $34.4M, operating cash flow $32.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $77.7M | +0.8% | +24% |
| Operating profit | $41.4M | +25% | +90% |
| Net earnings | $34.4M | -84% | +47% |
| Operating cash flow | $32.6M | -29% | 25× |
What changed
Revenue was $77.7M in Q1 2026, up 24% year over year and up 1% from the previous quarter. Net product sales was the largest line at 95% of revenue. Net product sales added $13.6M year over year (up 23%), 89% of the total change.
Operating profit was $41.4M, a 53.3% margin (up 18.3 points year over year). Of the extra revenue versus Q1 2025, 128% reached operating profit, above the 35% margin then. Total costs fell 11% while revenue rose 24%. The fastest-growing cost line was Research & development (+30%). Net earnings were $34.4M, up 47% year over year. The effective tax rate was 21.8%.
Operating cash flow was $32.6M (up 2405% year over year), 95% of net earnings. Non-cash charges added back $4.8M of depreciation and amortization. Working capital and other items used $6.6M.
Questions
What was Aurinia Pharmaceuticals' revenue in the first quarter 2026?
Aurinia Pharmaceuticals (AUPH) reported revenue of $77.7M for the first quarter 2026 (Q1 2026), +24% from a year earlier and +0.8% from the quarter before.
Was Aurinia Pharmaceuticals profitable in the first quarter 2026?
Operating profit was $41.4M (53.3% of revenue) and net earnings $34.4M.